Regional Use and Uptake of New and Expensive Cancer Medicines
Published 1.5.2021
Antineoplastic and immunomodulating agents is one of the fastest growing medicine groups. However, concerns have been raised about the availability of the latest cancer medicines and regional equality.
The purpose of this study is to produce new information on the regional use and uptake of new outpatient cancer medicines. This study examines the rate at which new treatments are introduced regionally as well as the explaining factors. The generated data are closely linked to the lack of regional guidance and knowledge of medicines identified by the Ministry of Social Affairs and Health as well as the themes of the ongoing health and social services reform.
Researchers
- Hanna Koskinen, Leading Researcher
- Terhi Kurko
Project Implementation Period
1.5.2021–31.12.2022. The project has ended.
